Nurse Care Management for Opioid Use Disorder Treatment
JAMA Internal Medicine · 01.12.2023 · 183 (12) · 1343
DOI: 10.1001/jamainternmed.2023.5701 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.12.2023. Verfasst von Paige D Wartko und 50 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Washington Health Research Institute, Seattle. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Few primary care (PC) practices treat patients with medications for opioid use disorder (OUD) despite availability of effective treatments.
Objective
To assess whether implementation of the Massachusetts model of nurse care management for OUD in PC increases OUD treatment with buprenorphine or extended-release injectable naltrexone and secondarily decreases acute care utilization. Design, Setting, and Participants The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a mixed-methods, implementation-effectiveness cluster randomized clinical trial conducted in 6 diverse health systems across 5 US states (New York, Florida, Michigan, Texas, and Washington). Two PC clinics in each system were randomized to intervention or usual care (UC) stratified by system (5 systems were notified on February 28, 2018, and 1 system with delayed data use agreement on August 31, 2018). Data were obtained from electronic health records and insurance claims. An implementation monitoring team collected qualitative data. Primary care patients were included if they were 16 to 90 years old and visited a participating clinic from up to 3 years before a system’s randomization date through 2 years after.
Intervention
The PROUD intervention included 3 components: (1) salary for a full-time OUD nurse care manager; (2) training and technical assistance for nurse care managers; and (3) 3 or more PC clinicians agreeing to prescribe buprenorphine. Main Outcomes and Measures The primary outcome was a clinic-level measure of patient-years of OUD treatment (buprenorphine or extended-release injectable naltrexone) per 10 000 PC patients during the 2 years postrandomization (follow-up). The secondary outcome, among patients with OUD prerandomization, was a patient-level measure of the number of days of acute care utilization during follow-up.
Results
During the baseline period, a total of 130 623 patients were seen in intervention clinics (mean [SD] age, 48.6 [17.7] years; 59.7% female), and 159 459 patients were seen in UC clinics (mean [SD] age, 47.2 [17.5] years; 63.0% female). Intervention clinics provided 8.2 (95% CI, 5.4-∞) more patient-years of OUD treatment per 10 000 PC patients compared with UC clinics ( P = .002). Most of the benefit accrued in 2 health systems and in patients new to clinics (5.8 [95% CI, 1.3-∞] more patient-years) or newly treated for OUD postrandomization (8.3 [95% CI, 4.3-∞] more patient-years). Qualitative data indicated that keys to successful implementation included broad commitment to treat OUD in PC from system leaders and PC teams, full financial coverage for OUD treatment, and straightforward pathways for patients to access nurse care managers. Acute care utilization did not differ between intervention and UC clinics (relative rate, 1.16; 95% CI, 0.47-2.92; P = .70). Conclusions and Relevance The PROUD cluster randomized clinical trial intervention meaningfully increased PC OUD treatment, albeit unevenly across health systems; however, it did not decrease acute care utilization among patients with OUD. Trial Registration ClinicalTrials.gov Identifier: NCT03407638
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Washington Health Research Institute, Seattle.
- Department of Biostatistics, School of Public Health, University of Washington, Seattle.
- Now with Genentech Inc, South San Francisco, California.
- The Emmes Company, Rockville, Maryland.
- Now with Kaiser Permanente Washington, Renton.
- Now with Department of Epidemiology and Biostatistics, Michigan State University, East Lansing.
Förderung
- NIDA NIH HHS
Zitieren
APA
Wartko, P. D., Bobb, J. F., Boudreau, D. M., Matthews, A. G., McCormack, J., Lee, A. K., Qiu, H., Yu, O., Hyun, N., Idu, A. E., Campbell, C. I., Saxon, A. J., Liu, D. S., Altschuler, A., Samet, J. H., Labelle, C. T., Zare-Mehrjerdi, M., Stotts, A. L., Braciszewski, J. M., …, & Burganowski, R. P. (2023). Nurse Care Management for Opioid Use Disorder Treatment. JAMA Internal Medicine, 183(12), 1343. https://doi.org/10.1001/jamainternmed.2023.5701
Vancouver
Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, et al. Nurse Care Management for Opioid Use Disorder Treatment. JAMA Internal Medicine. 2023;183(12):1343. doi:10.1001/jamainternmed.2023.5701
BibTeX
@article{Wartko2023,
author = {Wartko, Paige D and Bobb, Jennifer F and Boudreau, Denise M and Matthews, Abigail G and McCormack, Jennifer and Lee, Amy K and Qiu, Hongxiang and Yu, Onchee and Hyun, Noorie and Idu, Abisola E and Campbell, Cynthia I and Saxon, Andrew J and Liu, David S and Altschuler, Andrea and Samet, Jeffrey H and Labelle, Colleen T and Zare-Mehrjerdi, Mohammad and Stotts, Angela L and Braciszewski, Jordan M and Murphy, Mark T and Dryden, Douglas and Arnsten, Julia H and Cunningham, Chinazo O and Horigian, Viviana E and Szapocznik, José and Glass, Joseph E and Caldeiro, Ryan M and Phillips, Rebecca C and Shea, Mary and Bart, Gavin and Schwartz, Robert P and McNeely, Jennifer and Liebschutz, Jane M and Tsui, Judith I and Merrill, Joseph O and Lapham, Gwen T and Addis, Megan and Bradley, Katharine A and PROUD Trial Collaborators, PROUD Trial Collaborators and Ghiroli, Megan M and Hamilton, Leah K and Hu, Yong and LaHue, Jennifer S and Loree, Amy M and Murphy, Sean M and Northrup, Thomas F and Shmueli-Blumberg, Dikla and Silva, Angela J and Weinstein, Zoe M and Wong, Mark TinFook and Burganowski, Rachael P},
title = {Nurse Care Management for Opioid Use Disorder Treatment},
journal = {JAMA Internal Medicine},
year = {2023},
volume = {183},
number = {12},
pages = {1343},
doi = {10.1001/jamainternmed.2023.5701}
}
EUVIMED